The “Stepping Stone” Approach to Getting Longevity Drugs to Market
Getting geroprotective drugs to market for specific disease applications is the first step in eventually making them available for healthier aging.
School of Shrooms
Oregon’s grand experiment in training psychedelic facilitators is facing a tangle of ambiguity and red tape.
How to Make Coffee Without the Beans
“Beanless coffee” is making its way to store shelves, but will consumers give up their beloved cup of Joe for a more eco-friendly option?
Can Cultured Meat Ever Be More Than a Science Experiment?
Entrepreneurs are brewing up fish, meat, and fowl in spite of skeptics who say that lab-grown meat will never be feasible at an industrial scale.
2023 Predictions—the Good, the Bad, and the Ugly
What to expect in genetic engineering, neuroscience, psychedelics, longevity research, digital health, food, human performance, wellbeing, and of course, ChatGPT.
AI Versus Antibiotic Resistance
AI can help overcome both scientific and financial hurdles to tackle this serious threat to global health.
At-Home Blood Testing Just Got a Whole Lot Better
SiPhox’s coming silicon photonics technology seems to deliver on at least some of the promises Theranos made.
Alex Zhavoronkov: Live Long and Prosper
The maniacally focused founder of Insilico Medicine is going all in on AI to discover new medicines and extend lifespan.
What if We Didn’t Have to Test New Drugs on Animals?
As organ-on-a-chip technology comes of age, the bipartisan FDA Modernization Act 2.0 would remove the requirement that new drugs must undergo animal testing before human clinical trials.